England's Cancer Drugs Fund has been dealing with budget overruns and backlash from drugmakers and patients unhappy with the fund's decision to ax certain meds from its list. Now, the country's cost watchdogs are planning to take the reins and give the fund a much-needed makeover.
Novo Nordisk has forecast that currency hedging losses will leave it with an $850 million net loss for the year. But CEO Lars Rebien Sørensen thinks he may have landed on a new way to traverse that rough terrain: Build a plant in the U.S.
Massachusetts is joining the state-level push to tamp down drug prices. Lawmakers are proposing new disclosures about pharma's pricing decisions, just as they are in other states. But unlike California's move to limit price increases, for instance, Massachusetts could actually cap prices on specialty meds.
GlaxoSmithKline says that the people and products at its manufacturing site in Zebulon, NC, were never in peril from the bacteria for Legionnaires' disease detected this week in two cooling towers for the facility.
Mylan hopes its shareholders vote in favor of its hostile bid for Ireland's Perrigo. And it got a boost on Wednesday that may help convince them to do so at a shareholder meeting later this month.
The good news for Merck & Co.'s far-flung workforce: The job cuts hanging over your heads for the past five years are almost finished. The not-so-good news: Several thousand payroll reductions are yet to come.
Last month, Depomed criticized a sweetened, $33-per-share buyout offer from Horizon, claiming the all-stock proposal was "opportunistic" and took advantage of share-price fluctuations. So Horizon is doing something about it.
It isn't too often that drugmakers and journalists go head-to-head in court. But as part of Amgen's latest legal battle, it's asking a federal judge to force a reporter to testify about an article he wrote that prompted a shareholder suit against the company and to spell out how he got information about an abandoned clinical trial.
Industry watchers have pointed to a slowdown in pharma's emerging markets growth as a worrying sign for companies that have been heavily targeting developing nations while the U.S. and European markets stagnate. But just how slow has the growth become?
Money makes the world go round--the patent world, that is. That's the word from hedge funder Kyle Bass, who has been targeting drug patents he calls "low quality," and shorting pharma stocks along the way.
Makers of multiple myeloma drugs are vying for position in a space that's heating up, pointing to promising survival data to help their drugs gain ground. But if they tweaked their marketing strategies, they could have an easier time.
Roche has been on a legal roller coaster with its acne drug Accutane. Facing thousands of claims that the drug triggers inflammatory bowel disease, the Swiss drugmaker is now enjoying a high point, as an appeals court reversed a $25 million verdict against the company.
As the fourth market entrant in a hotly contested group of new-age anticoagulants, Daiichi Sankyo's Lixiana (edoxaban) has some ground to make up. Luckily, it got a boost in the U.K. that could help it build momentum.
After detecting the bacteria for Legionnaires' disease in its cooling tower, GlaxoSmithKline temporarily closed a manufacturing plant in North Carolina on Tuesday and sent employees home while it investigates the impact, if any, on the medications manufactured there. The discovery comes as an outbreak of the infection has resulted in a dozen deaths in New York.
There's just over two weeks left until Mylan's shareholders vote on its proposed hostile takeover of Perrigo, and the Irish target is using the time to meet with shareholders of both companies. Right now, its leaders feel "good about where they stand," according to Bernstein analyst Ronny Gal--but there are some question marks hanging over them, too.
Pfizer plans to pay doctors in England to prescribe its drug Lyrica. But don't jump to conclusions. These payments are in a category all their own.
Australian vaccines maker CSL has plenty of wherewithal to make some deals, CEO Paul Perreault says, but he's wary of the prices paid by other drugmakers. Big Pharma's penchant for biotech deals has created "a bit of a bubble," in Perreault's view.
Lundbeck has long touted the cognitive benefits of its depression med, Brintellix, rolling out data that shows the drug improves patients' thinking, decision-making and attention better than its competition. Now the company could be gaining more of an edge for its med, as the FDA accepted a supplemental new drug application to add information about Brintellix's effect on cognitive problems to its label.
CVS Health has no intention of shelling out more than it has to on the new PCSK9 drugs. It's been saying so for more than a year--and now, it has taken a double-barreled shot at the next-gen cholesterol fighters.
Last week, Baxalta rejected a $30 billion buyout bid from Shire, pointing to its youth, its standalone prospects and a portfolio that just wouldn't jibe with the Irish pharma's. On Monday, its CEO hammered those points home once again for investors--and stressed that Shire's proposal, as it stands, is "wholly inadequate."